Table 2. Relationship between miR-125a-5p expression level and clinicopathologic parameters of breast cancer.
| Variables | Number of cases N = 300 | miR-125a-5p Low expression | High expression | r | p-Value |
|---|---|---|---|---|---|
| Stage | −0.104 | 0.071 | |||
| I | 121 | 58 | 63 | ||
| II | 133 | 70 | 63 | ||
| III | 46 | 30 | 16 | ||
| Grade | −0.167 | 0.004 | |||
| I | 128 | 54 | 74 | ||
| II | 106 | 64 | 42 | ||
| III | 66 | 40 | 26 | ||
| Lymph-node status | −0.166 | 0.004 | |||
| Negative | 177 | 81 | 96 | ||
| Positive | 123 | 77 | 46 | ||
| Estrogen receptor status | −0.045 | 0.436 | |||
| Negative | 101 | 50 | 51 | ||
| Positive | 199 | 108 | 91 | ||
| Progesterone receptor status | 0.016 | 0.785 | |||
| Negative | 125 | 67 | 58 | ||
| Positive | 175 | 91 | 84 | ||
| Her2/Neu status | 0.108 | 0.061 | |||
| Negative | 202 | 114 | 88 | ||
| Positive | 98 | 44 | 54 |
Low expression: < or = Median, High expression: > Median, P: Two-sided χ2 test